Dr. Le is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-794-5446
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
UMass Chan Medical SchoolResidency, Internal Medicine, 2010 - 2013
Peking Union Medical CollegeClass of 2003
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2027
GA State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2017 - 2026
WA State Medical License 2023 - 2026
LA State Medical License 2023 - 2025- Join now to see all
Clinical Trials
- Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Jul 25
Publications & Presentations
PubMed
- Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review.Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang
Journal of Thoracic Oncology. 2024-11-30 - The changing treatment landscape of EGFR-mutant non-small-cell lung cancer.Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel S W Tan
Nature Reviews. Clinical Oncology. 2024-11-29 - 2 citationsCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01
Journal Articles
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsPaul K Paik, Xiuning Le, The New England Journal of Medicine
- Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)Xiuning Le, Jianjun Zhang, John V Heymach, Clinical Lung Cancer
Lectures
- Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection.2019 ASCO Annual Meeting - 6/1/2019
- Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsMay 2020
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsMay 2020
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsMay 2020
- Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)September 2018
- Join now to see all
Press Mentions
These Early Signs of Lung Cancer Are Often Missed, Oncologists SaySeptember 27th, 2024- New Results from the Investigational Agent BAY 2927088 in HER2-Mutant Non-Small Cell Lung Cancer (NSCLC) Presented at WCLCSeptember 9th, 2024
- BAY 2927088 Demonstrates 'Rapid, Substantial and Durable Responses' in Patients with HER2-Mutant NSCLCSeptember 9th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
